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http://dxAbstract: Expectation and previous experience are both well established key mediators of placebo
and nocebo effects. However, the investigation of their respective contribution to placebo and no-
cebo responses is rather difficult because most placebo and nocebo manipulations are contaminated
by pre-existing treatment expectancies resulting from a learning history of previous medical inter-
ventions. To circumvent any resemblance to classical treatments, a purely psychological placebo-
nocebo manipulation was established, namely, the ‘‘visual stripe pattern–induced modulation of
pain.’’ To this end, experience and expectation regarding the effects of different visual cues (stripe
patterns) on pain were varied across 3 different groups, with either only placebo instruction (expec-
tation), placebo conditioning (experience), or both (expectation 1 experience) applied. Only the com-
bined manipulation (expectation 1 experience) revealed significant behavioral and physiological
placebo–nocebo effects on pain. Two subsequent experiments, which, in addition to placebo and no-
cebo cues, included a neutral control condition further showed that especially nocebo responses
were more easily induced by this psychological placebo and nocebo manipulation. The results
emphasize the great effect of psychological processes on placebo and nocebo effects. Particularly, no-
cebo effects should be addressed more thoroughly and carefully considered in clinical practice to pre-
vent the accidental induction of side effects.
Perspective: Even purely psychological interventions that lack any resemblance to classical pain
treatments might alter subjective and physiological pain correlates. A manipulation of treatment
expectation and actual treatment experience were mandatory to elicit this effect. Nocebo effects
were especially induced, which indicated the necessity for prevention of accidental side effects be-
sides exploitation of placebo responses.
ª 2016 The Authors. Published by Elsevier Inc. on behalf of the American Pain Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ence, expectation.lacebo and nocebo effects represent ideal examples
for the tremendous effect of psychological pro-
cesses on pain.4,5,40 They have been shown to
result in alterations of biological pain markers19,41 and
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.doi.org/10.1016/j.jpain.2015.10.010modulatory mechanisms such as distraction.9 Expecta-
tion and previous experience are key mediators of pla-
cebo hypo- or nocebo hyperalgesia36 and their effects
and interactions have been shown in a variety of experi-
mental paradigms.4,12,32 In 2 seminal studies, the
influence of previous learning for the generation of a
subsequent placebo effect was shown: After a placebo
conditioning procedure (placebo cream paired with
low levels of pain, control cream paired with higher
levels of pain) participants showed placebo analgesia in
a subsequent test phase when pain stimuli were
actually of identical physical intensity.38,39 Since then, it
has been shown that even social observational learning
is capable of eliciting placebo11 and nocebo37 effects,
and also manipulations of expectations by suggestion
or verbal instruction were found to induce placebo ef-
fects.1,14 In general, the strongest placebo and nocebo203
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were manipulated in concert.10,12,39 However, it remains
to be shown whether the 2 mechanisms act
independently from each other in a mainly additive
manner or if they result in an interactive (ie, over or
under additive) modulation of pain.9,16
With regard to medical practice, the repeated
encounter of an intervention in association with a spe-
cific stimulus or context (eg, capsule, white coats, the
hospital itself) leads to the generation of cues that pre-
dict the actual drug or treatment effect, and thus shape
future treatment expectations. As a result, these cues
might elicit conditioned (placebo and nocebo) reactions
themselves, such as symptom decrease or increase.16,40 It
was shown that previous experiences with an
intervention modulate the placebo response and
further that placebo effects are embedded in an
individual’s history of medical treatments.15,23
So far, placebo and nocebo paradigms of pain were
conducted usually with application of placebo agents
that provided pharmacological plausibility or resembled
medical interventions, for example, inert creams,18 prick-
ling nasal sprays,33 injections,42 sham acupuncture,26
fake low-current electrical stimulation,13 etc. Conse-
quently, investigation of the contribution of experience
and expectation to placebo and nocebo effects sepa-
rately is rather difficult, because the usage of medical
sham treatments might always activate expectations
that are the result of individual treatment experiences.17
We concluded that experimentally induced placebo or
nocebo effects are likely contaminated by expectations
as a result of the individual’s history of previous treat-
ments. Therefore, the present study was designed to
manipulate experience and expectation independently
and to forego any resemblance to popular pain treat-
ments by taking advantage of a purely psychological pla-
cebo–nocebo paradigm. To this end, in experiment 1 we
compared 3 groups of participants. One group received a
written placebo–nocebo instruction, which provided in-
formation about the alleged powerful analgesic and
proalgesic effects of watching certain black and white
stripe patterns (expectation). The second group (experi-
ence) underwent placebo–nocebo conditioning with
these stripe patterns as visual cues, and the third group
received the placebo–nocebo instruction and the condi-
tioning procedure (expectation 1 experience). In a sub-
sequent test phase, placebo and nocebo responses
were measured by applying identical thermal pain
stimuli. In experiments 2a and b, an additional neutral
control stimulus was introduced to determine whether
the manipulation resulted primarily in a placebo or a no-
cebo effect. In contrast to previous studies, which used
predictive cues that solely announced different up-
coming pain intensities,2,31 in the present experiments
participants were informed about an actual pain
modulatory effect that would result from observation
of the described visual stripe patterns.
Our main goal was to test whether a purely psycholog-
ical placebo–nocebo manipulation would be feasible to
induce placebo hypo- and nocebo hyperalgesia. Further-
more, we aimed to elaborate whether 1) expectationand experience would modulate pain independently
from each other (additive contribution), 2) a combina-
tion of expectation and experiencewould lead tomutual
interference and thus decreased responses
(underadditive interaction), or 3) the manipulation of
expectation and experience would result in a dispropor-
tionally pronounced placebo–nocebo response (overad-
ditive interaction).Methods
Participants
In experiment 1, 65 participants (32 women, mean
[M] = 23.62 years, SD = 3.18) were randomly allocated
to 1 of the 3 experimental groups. Participants of the
different groups did not statistically differ from each
other regarding their individual pain threshold (PT;
P = .99), pain sensitivity (P = .99),34 or trait anxiety
(P = .22).35 Participants of the expectation group were
slightly younger (M = 21.86 years, SD = 2.96) than partic-
ipants of the experience group (M = 24.65 years,
SD = 3.45) and the combined expectation 1 experience
group (M = 24.39 years, SD = 2.44), F1,64 = 5.87, P = .01.
In experiment 2a, 29 participants took part; of those, 3
participants were excluded because of technical prob-
lems with pain stimulation or insufficient understanding
of the experimental procedure, which resulted in a final
sample of 26 participants (14 women, age
M = 25.27 years, SD = 6.33).
In experiment 2b, 23 participants took part; of those, 3
participants were excluded because of exceedingly high
PTs, which resulted in a final group size of 20 (14 women,
age M = 23.20 years, SD = 2.78).
All participants of experiments 1 and 2a and b had no
current, or history of, chronic pain, neurological or psy-
chiatric disorder, and did not take any pain medication
24 hours before the experiment (self-report). Informed
consent was obtained from all participants before partic-
ipation in the study. The experimental procedure was
approved by the institutional review board of the
medical faculty of the University of W€urzburg.
Thermal Pain Stimulation
Pain stimuli were delivered using a Somedic MSA
thermal stimulator (Somedic Sales AB, H€orby, Sweden)
and a Peltier thermode with an active surface of
25 50mm. Before the actual experiment, the individual
PT was assessed. The average PT temperature in experi-
ment 1 was M = 46.56C, SD = 2.34C (groups did not
differ, F < 1), and M = 45.51C, SD = 2.88C in experiment
2a. Thermal stimulation started from a baseline temper-
ature defined as 10C lower than PTand increased with a
speed of 5C/s until low pain (PT), medium pain
(PT 1 0.5C), or high pain (PT 1 1C) was achieved,
respectively.
In experiment 2b, placebo, control, and nocebo tem-
peratures were generated on the basis of a calibration
procedure (similar to the procedure described previ-
ously19) during which the participants evaluated the
pain intensity of 10 heat pain stimuli (range
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0–100). Pain ratings were fitted with a linear regression
and stimulation levels were chosen, which approximated
VAS 40, 50, and 60 (45.14C, 46.16C, and 47.18C, respec-
tively). This procedure was applied to guarantee 3
distinct temperature levels during conditioning despite
individual differences in pain perception.
All participants rated the pain stimuli regarding pain
intensity and pain unpleasantness using a digitized VAS
ranging from 0 = ‘‘no pain’’ at all to 100 = ‘‘unbearable
pain’’ (pain intensity), and from 0 = ‘‘not unpleasant at
all’’ to 100 = ‘‘extremely unpleasant’’ (pain unpleasant-
ness) using a button press of a computer keyboard.Skin Conductance Measurement
For skin conductance recording, two 22/10 mm Ag/
AgCl surface electrodes (electrode gel: 0.5% NaCl) were
attached to the thenar and hypothenar eminence of
the participant’s nondominant hand. The signal was
sampled with 1000 Hz, with constant application of
0.5 V, using a V-Amp amplifier (Brain Products Inc, Mu-
nich, Germany) and recording software (Brain Vision
Recorder, V. 1.10, Brain Products Inc). Skin conductance
responses (SCRs) were quantified as highest positive
deflection 1 to 13 seconds after pain stimulation onset,
relative to a 1-second baseline (Brain Vision Analyzer
2.0., Brain Products Inc). Two participants of experiment
1 (1 of the expectation group; 1 of the combined
expectation 1 experience group) showed no responses
during the whole test phase and were excluded from
the SCR data analysis.Placebo–Nocebo Manipulation and
Experimental Procedure
Experiment 1
Participants were instructed according to their
experimental group either to take part in a study on
the processing of thermal pain (experience), or that
they were going to watch horizontal and vertical black
and white stripe patterns, which reportedly had been
shown in studies by renowned scientists to drastically
decrease or increase the perception of pain (expecta-
tion, expectation 1 experience). Participants then
were familiarized with the pain stimulation and rating
procedure, and proceeded to the conditioning phase
consisting of 30 trials (15 placebo cues and low pain;
15 nocebo cues and high pain), followed by the test
phase consisting of 20 trials (10 placebo cues and
high pain; 10 nocebo cues and high pain). During
each trial, the respective visual placebo or nocebo
cue was presented in the center of the screen for
20 seconds. Three seconds after cue onset the pain
stimulation was started, reached the target tempera-
ture after approximately 2 seconds, and remained at
plateau for 3 seconds. After the thermode had cooled
to baseline level, participants rated their pain experi-
ence. Each trial was separated by an intertrial interval
of 4 to 5 seconds (randomized) during which a central
fixation cross was presented. During the conditioningphase, the expectation group received in random or-
der the same number of high pain and low pain stim-
ulations as the other groups, while watching a central
fixation cross. In the subsequent test phase all partici-
pants watched placebo and nocebo cues again and
received always the identical high pain stimuli
(Fig 1). At the end of the experiment, nocebo and
placebo cues were presented again and participants
were asked to indicate how painful they remember
the pain stimulation after the respective visual cue (re-
called pain ratings). Recalled pain ratings of the expe-
rience and the expectation 1 experience groups likely
reflected the test phase and the conditioning phase
when pain stimulation actually was different during
the placebo and nocebo trials and therefore need to
be interpreted cautiously. Ratings of the expectation
group instead referred to the instruction in the begin-
ning of the experiment and probably reflect the
manipulation of expectancy because participants
never received any contingent pairing of pain stimula-
tion and placebo or nocebo during conditioning.
Experiment 2a
Participants received a similar manipulation as the
combined expectation 1 experience group except for
the introduction of a third cue (gray square) that served
as a control condition and was explained to the partici-
pants to have no influence on the perception of pain at
all. After participants read the placebo and nocebo in-
structions, they were presented with the visual placebo
and nocebo cues and evaluated their expectation
regarding a pain increase versus a decrease in effect of
the 3 visual stimuli using a 9-point Likert scale that
ranged from pain very much decreased (4) to pain
very much increased (14). Placebo conditioning similarly
consisted of the presentation of the placebo cue paired
with low pain, the nocebo cue paired with high pain,
and the neutral cue paired with medium pain (10 trials
per condition). During the subsequent test phase, cues
were presented always combined with high pain (10
trials per condition; Fig 1).
Experiment 2b
The paradigm was the same as in experiment 2a, with
the exception that placebo, control, and nocebo temper-
atures were approximated to the subjective VAS
ratings corresponding to 40, 50, and 60, respectively. Con-
ditioning consisted of 15 trials per condition as in exper-
iment 1. During the test phase, pain stimuli were always
equivalent to the pain stimulation level of the control tri-
als during conditioning (10 trials per condition; Fig 1).Statistical Analysis
For experiment 1, pain-evoked SCRs, sensory, and
affective pain ratings of the test phase were
analyzed by applying a 3-factorial repeated measures
analysis of variance (ANOVA) with the within-subjects
factor condition (placebo vs nocebo), the within-
subjects factor time (trials 1-5 vs trials 6-10), and
the between-subjects factor experimental group
Figure 1. Procedure of experiments 1 and 2. In experiment 1 participants were first instructed according to the respective experi-
mental condition: experience (control instruction: ‘‘You are going to take part in a study on heat pain perception’’) versus expectation,
or expectation and experience (placebo–nocebo instruction: ‘‘You are going to watch black and white stripe patterns which were
found to alter the perception of pain’’). Afterwards, participants underwent placebo–nocebo conditioning (experience and expecta-
tion 1 experience group) and watched visual stripe patterns paired with the nocebo or placebo temperature, or watched fixation
crosses (Fix.Cross) instead while the same number of pain stimuli were administered (expectation group). At the end of the experi-
ment, participants provided recalled sensory and affective pain ratings for nocebo and placebo cues, respectively. In experiment
2a, only the expectation 1 experience condition was realized. In addition, a third control stimulus was introduced (gray square),
which was stated to have no influence on pain, and was paired with intermediate pain stimulations during conditioning. In the
test phase of both experiments, placebo, nocebo, or control cueswere pairedwith a pain stimulus equivalent to the nocebo pain stim-
uli from the conditioning phase. Experiment 2b was equivalent to experiment 2a, except for the number of conditioning trials (15).
Further, temperature levels were calibrated to VAS 40, 50, and 60; the temperature during the test phase was the same as in control
trials during conditioning. PT = pain threshold; LOW = PT temperature (experiments 1 and 2a) or VAS 40 (experiment 2b);
MEDIUM = PT plus 0.5C (experiments 1 and 2a) or VAS 50 (experiment 2b), HIGH = PT plus 1.0C (experiments 1 and 2a) or VAS 60
(experiment 2b).
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As a manipulation check, results of the conditioning
phase were analyzed by applying 2-factorial repeated
measures ANOVAs with the within-subjects factor pain
stimulation level (low vs high pain) and the aforemen-
tioned between-subjects factor group. Similarly, recalled
pain ratings at the end of the experiment were analyzed
by applying a 2-factorial repeated measures ANOVA
with the within-subjects factor placebo versus nocebo
and pain stimulation level (low vs high pain) and the
between-subjects factor group.
For experiment 2a and b, sensory and affective pain
ratings of the test phase were analyzed by applying
2-factorial repeated measures ANOVAs with the within-
subjects factor condition (nocebo vs control vs placebo)
and the within-subjects factor time (trials 1-5 vs trials
6-10). Similar to experiment 1, results of the conditioning
phase were analyzed by applying a repeated measures
ANOVA with the within-subjects factor pain stimulation
level (low vs medium vs high pain). Associations of painratings during conditioning and the subsequent
test phasewere investigatedwith linear correlation anal-
ysis of nocebo > placebo, control > placebo and
nocebo > control difference scores respectively, for sen-
sory and affective pain ratings, separately for each exper-
imental group. When necessary, Greenhouse–Geisser
corrections of degrees of freedom were applied. Post
hoc comparisons were realized using planned contrasts
or pairwise t-tests. A priori significance level was set at
P < .05, 2-tailed. Partial h2 (hp




The results of the conditioning phase revealed a suc-
cessful differentiation between the different thermal
pain stimulation levels, for sensory pain ratings,
F1,62 = 235.54, P < .001, hp
2 = .79, and affective pain rat-
ings, F1,62 = 152.87, P < .001, hp
2 = .71, Fig 2A). Similarly,
Figure 2. Experiment 1: Mean (6SEM) of sensory and affective pain ratings are depicted for each experimental group. In the con-
ditioning phase (A) pain ratings were higher for high compared with low painful stimuli in all experimental groups. In the test phase
(B) affective pain ratings were higher for nocebo compared with placebo trials only for the expectation 1 experience group.
***P < .001. Abbreviation: SEM, standard error of the mean.
Reicherts et al The Journal of Pain 207skin conductance responses were higher in response to
high compared with low thermal stimulation,
F1,62 = 16.37, P < .001, hp
2 = .21. In this phase of the exper-
iment, no differences were observed between the 3
experimental groups.
In the subsequent test phase, visual placebo and no-
cebo cues were presented again, but this time thermal
pain stimuli were identical. Placebo and nocebo effects
were revealed as follows: The analysis of SCR in response
to the thermal pain stimuli indicated a significant 3-way
interaction of condition (placebo vs nocebo), time (trials
1-5 vs trials 6-10), and group (expectation, experience,
expectation 1 experience), with F2,60 = 3.16, P = .05,
and hp
2 = .10, as a result of higher SCR during early no-
cebo compared with placebo trials (trials 1-5) in the
expectation 1 experience group only, with t21 = 2.90,
and P = .009 (Fig 3).Affective pain ratings revealed a significant effect of
condition, with F1,62 = 12.37, P < .001, and hp
2 = .17,
because of higher unpleasantness ratings for nocebo
compared with placebo trials. This effect was further
qualified by a significant interaction of condition and
experimental group, with F2,62 = 4.28, P = .02, and
hp
2 = .12. Separate ANOVAs for each group revealed a
significant effect of condition for the combined
expectation 1 experience group, with F1,22 = 16.47,
P < .001, and hp
2 = .43. Instead, this effectwas neither sig-
nificant for the experience (P = .88), nor the expectation
group (P = .11, Fig 2B). There was no effect of time
(F1,62 = 0.49, P = .83, hp
2 = .001), or a significant interac-
tion of time and condition for affective pain ratings
(F1,62 = 0.11, P = .74, hp
2 = .01).
Corroborating these findings, post hoc analysis of no-
cebo minus placebo difference scores in affective pain
Figure 3. Experiment 1 test phase: SCR (mean 6 SEM) in response to the thermal pain stimuli are depicted for each experimental
group, split by the first and second half of the test phase. SCRswere increased in the beginning of the test phase for nocebo compared
with placebo trials only for the expectation 1 experience group. **P < .01. Abbreviation: SEM, standard error of the mean.
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for the combined expectation 1 experience group
compared with the experience group (t62 = 2.88,
P = .005), and a marginally significantly greater differen-
tiation compared with the expectation group (t62 = 1.81,Figure 4. Experiment 1: Depicted are nocebo minus placebo
difference scores across all 3 experimental groups
(mean 6 SEM). The expectation 1 experience group showed
the strongest differentiation of placebo and nocebo trials, fol-
lowed by the expectation and experience groups. P > .10 (not
significant [n.s.]); yP < .10; **P < .01. Abbreviation: SEM, stan-
dard error of the mean.P = .08, Fig 4). No differences emerged between the
expectation and the experience groups (t62 = 1.11,
P = .27).
Sensory pain ratings of the test phase were higher for
nocebo compared with placebo trials (F1,62 = 9.38,
P = .003, hp
2 = .13), irrespective of experimental group
or time interval of the test phase. There was no general
difference in sensory pain ratings across the experimental
groups (F2,62 = 1.51, P= .23,hp
2 = .05). Exploratory compar-
isons of nocebo and placebo trials revealed a similar pic-
ture as for the affective pain ratings, that is, a significant
difference for the combined expectation 1 experience
group (t22 = 3.40, P = .003), whereas the same comparison
was only marginally significant for the expectation group
(t22 = 1.96, P = .064) and not significant for the experience
group (t19 = 0.49, P = .63, Fig 2B).
Recalled affective pain ratings at the end of the exper-
iment were higher for nocebo compared with placebo
trials (F1,62 = 22.38, P < .001, hp
2 = .27) across all groups.
Recalled sensory pain ratings were higher for nocebo
compared with placebo trials as well (F1,62 = 22.35,
P < .001, hp
2 = .27). Interactions of condition and group




PAIN RATINGS M SD
Experience (n = 20) Sensory 12.65 27.01
Affective 8.60 26.91
Expectation (n = 22) Sensory 5.10 16.36
Affective 9.95 20.23
Expectation1 experience (n = 23) Sensory 19.17 18.74
Affective 21.87 21.56
NOTE. Nocebo > placebo difference scores of recalled sensory and affective pain
ratings are shown for each group.
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ence scores between the conditioning and the test phase
revealed a significant linear trend solely for the com-
bined expectation 1 experience group (affective pain
ratings: r = .54, P = .01; sensory pain ratings, r = .50,
P = .01), which indicated a relation of reinforced expecta-
tions and subsequent recall of the placebo–nocebo
response. In contrast, no significant correlations in the
2 other groups were observed (experience: affective
pain ratings, r = .23, P = .32 and sensory pain ratings,
r = .17, P = .47; expectation: affective pain ratings,
r = .27, P = .23 and sensory pain ratings, r = .21,
P = .35).
In conclusion, these results from experiment 1 showed
significant placebo and nocebo responses and also indi-
cated that their magnitude was predicted by the differ-
ence between high and low pain ratings during the
learning phase, but only in the group for which instruc-
tion and conditioning were combined.Experiments 2a and b
Experiments 2a and b were designed to follow-up the
results of experiment 1 and to determine whether the
observed effects were driven more by a placebo or a no-
cebo response. In experiment 2a, a priori expectancy rat-
ings varied significantly across the different condition
cues (F2,50 = 15.44, P < .001, hp
2 = .38). Participants ex-
pected the nocebo stripe pattern to result in more pain
compared with the control pattern (F1,25 = 13.16,
P = .001, hp
2 = .35) and with the placebo pattern
(F1,25 = 16.91, P < .001, hp
2 = .40), which they expected
to lead to less pain than the control pattern (gray square)
(F1,25 = 13.15, P = .001, hp
2 = .30, Fig 5).
In the conditioning phase of experiment 2a, affective
pain ratings varied across the 3 pain stimulation levels
(F2,50 = 43.00, P < .001, hp
2 = .63). Participants successfully
differentiated between high and medium (F1,25 = 27.31,Figure 5. Experiment 2a: Expectancy ratings (mean6 SEM) ob-
tained in the beginning of the experiment; participants ex-
pected less pain during placebo and more pain during nocebo
trials compared with neutral control trials. **P < .01;
***P < .001. Abbreviation: SEM, standard error of the mean.P < .001, hp
2 = .52), high and low (F1,25 = 60.42,
P < .001, hp
2 = .71), and also between low and medium
pain stimuli (F1,25 = 13.19, P = .001, hp
2 = .35). Similarly,
sensory pain ratings varied across the pain stimulation
levels (F2,50 = 50.12, P < .001, hp
2 = .67). Participants suc-
cessfully differentiated between high and medium
(F1,25 = 44.37, P < .001, hp
2 = .64), high and low
(F1,25 = 79.93, P < .001, hp
2 = .76), and also between low
and medium pain stimuli (F1,25 = 13.19, P = .001,
hp
2 = .35, Fig 6A). Likewise, pain-related SCRs were
modulated by the different pain stimuli (F2,50 = 17.31,
P < .001, hp
2 = .41). SCRs were increased for high
compared with low (F2,50 = 27.40, P < .001, hp
2 = .52)
and medium (F2,50 = 17.92, P < .001, hp
2 = .42) thermal
pain stimulation. Medium and low pain stimuli were
not significantly different from each other (F2,50 = 0.27,
P = .61, hp
2 = .01).
In the test phase, affective pain ratings varied across
the 3 different conditions (F2,50 = 4.21, P = .02,
hp
2 = .14). Pain stimuli in nocebo trials were rated more
unpleasant than in placebo trials (F1,25 = 7.04, P = .01,
hp
2 = .22), but only slightly more unpleasant compared
with pain stimuli in control trials (F1,25 = 3.41, P = .08,
hp
2 = .12). Pain stimuli in placebo trials were rated similar
to pain stimuli in control trials (F1,25 = 0.93, P = .35,
hp
2 = .04, Fig 6B). The comparison of nocebo > control
and control > placebo difference scores was not signifi-
cant (t25 = 0.65, P = .52). No effect of time or an interac-
tion of time and condition were detected. Analysis of
pain intensity revealed similar but more pronounced ef-
fects. Sensory pain ratings also varied across the 3
different conditions (F2,50 = 7.61, P = .001, hp
2 = .23,
Fig 6B). Pain stimuli in nocebo trials were rated as more
painful than in placebo trials (F1,25 = 13.44, P = .001,
hp
2 = .35), and in control trials (F1,25 = 5.32, P = .03,
hp
2 = .18). Pain stimuli in placebo trials were rated only
nonsignificantly lower than in control trials
(F1,25 = 2.56, P = .12, hp
2 = .09). The comparison of
nocebo > control and control > placebo difference scores
was not significant (t25 = 0.76, P = .45). No effect of time
or an interaction of time and condition was detected.
Pain-related SCR showed no modulation according to
the different conditions during the test phase. Affective
pain ratings for placebo > control trials of the
conditioning and the test phase were positively corre-
lated (r = .49, P = .01). In addition, sensory pain ratings
for nocebo > control trials of the conditioning and the
test phase were slightly correlated (r = .35, P = .08). All
other correlations failed to reach significance.
In the conditioning phase of experiment 2b, affective
pain ratings also varied across the 3 pain stimulation
levels (F2,38 = 54.23, P < .001, hp
2 = .74). Participants
differentiated between high and medium (F1,19 = 49.33,
P < .001, hp
2 = .72), high and low (F (1,19) = 64.42,
P < .001, hp
2 = .77), and between low and medium pain
stimuli (F1,19 = 22.33, P = .001, hp
2 = .54). Sensory pain rat-
ings also varied across the different pain stimulation
levels (F2,38 = 60.37, P < .001, hp
2 = .76). Participants suc-
cessfully differentiated between high and medium
(F1,19 = 60.00, P < .001, hp
2 = .76), high and low
(F1,19 = 68.37, P < .001, hp
2 = .78), and between low and
Figure 6. Experiment 2a: Mean (6SEM) of sensory and affective pain ratings are depicted for each experimental condition. In the
conditioning phase (A) pain ratings significantly differentiated between low,medium, and high pain stimuli. In the test phase (B) sen-
sory and affective pain ratings for nocebo trials were rated higher than placebo and control trials, although ratings for placebo
and control trials did not differ. n.s., P > .12 (not significant); yP < .12; *P < .05; ***P # .001. Abbreviation: SEM, standard error of
the mean.
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2 = .57, Fig 7A) pain
stimuli.
In the test phase of experiment 2b, affective pain rat-
ings varied across the 3 different conditions
(F2,38 = 13.79, P < .001, hp
2 = .42, Fig 7B). Pain stimuli in
nocebo trials were rated as more unpleasant than in pla-
cebo trials (F1,19 = 19.61, P < .001, hp
2 = .51), and in con-
trol trials (F1,19 = 17.58, P < .001, hp
2 = .48). Pain stimuli
in placebo trials were rated similar to those during con-
trol trials (F1,19 = 0.74, P = .40, hp
2 = .04).
Nocebo > control difference scores (M = 6.79;
SD = 7.24) were significantly higher compared with
control > placebo difference scores (M = 1.06;
SD = 5.50, t19 = 3.06, P = .007). Sensory pain ratings also
varied across the different conditions (F2,38 = 13.79,
P < .001, hp
2 = .42). Stimuli in nocebo trials were rated
more intense than in placebo trials (F1,19 = 10.57,
P = .004, hp
2 = .36), and significantly more intenseFigure 7. Experiment 2 b: Mean (6SEM) sensory and affective pain
ditioning phase (A) pain ratings significantly differentiated between
and affective pain ratings for nocebo trialswere ratedhigher thanpla
trials did not differ. n.s., P > .10 (not significant); **P < .01; ***P < .0compared with pain stimuli in control trials
(F1,19 = 19.19, P < .001, hp
2 = .50). Pain stimuli in placebo
trials were rated similar to pain stimuli in control trials
(F1,19 = 1.91, P = .18, hp
2 = .09, Fig 7B).
Nocebo > control difference scores (M = 6.31;
SD = 6.44) were significantly higher compared with
control > placebo difference scores (M = 1.62;
SD = 5.25, t19 = 3.61, P = .002).
No significant effect of time (F1,19 = 2.89, P = .11,
hp
2 = .13) or an interaction of time and condition
(F2,38 = 0.76, P = .93, hp
2 = .004) was detected. There
was no significant correlation between pain ratings of
the conditioning phase and the test phase. Taken
together, the behavioral results from experiment 2a
and b replicate the findings from experiment 1 and sug-
gest that the manipulation of expectation together with
experience induces stronger nocebo than placebo
effects.ratings are depicted for each experimental condition. In the con-
low,medium, and high pain stimuli. In the test phase (B) sensory
cebo and control trials, although ratings for placebo and control
01. Abbreviation: SEM, standard error of the mean.
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The present study showed a significant placebo and
nocebo effect on pain that resulted from a purely psy-
chological placebo–nocebo manipulation. Importantly,
this effect was only observed when both expectation
and experience were manipulated as indicated by signif-
icant differences for affective—and to lesser degree for
sensory—pain ratings and higher SCRs in the early no-
cebo compared with placebo trials in the
expectation 1 experience group (experiment 1). These
findings suggest an overadditive interaction of experi-
ence and expectancy, which is most likely a result of rein-
forced expectations.
Similarly, pain ratings of the acquisition and the test
phase revealed only for the combination of expectation
and experience a significant relationship, which suggests
a potential transfer of the initial learning experience to
the subsequent placebo–nocebo response. However,
this correlation was weaker and only partially replicated
for affective pain ratings in experiment 2a, when 3 visual
cues were introduced. In experiment 1, the effect of a
single placebo–nocebo instruction (expectation) was
rather small, but still more pronounced than a
conditioning procedure (experience), which did not
result in any differences of pain perception between pla-
cebo and nocebo trials during the test phase. Although
the present placebo–nocebo agent was admittedly ab-
stract and novel to all participants, they anticipated a
pain modulatory influence of the different visual pat-
terns as indicated by the expectancy ratings of experi-
ment 2a. Finally, pain ratings of experiment 2a and
especially 2b suggest that nocebo effects can be more
easily induced by a purely psychological placebo and no-
cebo manipulation, as revealed by a stronger differenti-
ation between nocebo and control trials compared with
placebo and control trials. The present results are in line
with earlier findings that showed no or rather weak
conditioned placebo responses when no further placebo
instruction suggestive of analgesia was given.1,27,39
Placebo conditioning paradigms so far mostly provided
a physical, medicinal agent (eg, creams or pills) as a
conditioned stimulus, which might be much more easily
associated with the modulation of pain than a simple
visual stimulus. Consequently, the repeated pairing of
totally pain-unrelated visual cues with different levels
of thermal pain might result in smaller conditioned pla-
cebo–nocebo responses and thus only small alterations
of pain processing during a test phase. Therefore, a psy-
chological placebo paradigm presumably depends on
additional cognitive support such as a placebo instruc-
tion. However, just recently Jensen et al20 induced pla-
cebo hypoalgesia by applying a behavioral
conditioning procedure without any further verbal sug-
gestions. They presented neutral faces together with
either higher (nocebo) or lower (placebo) pain stimuli
which led to a corresponding modulation of pain ratings
when the actual pain stimulation was identical during a
test phase and persisted even when the cue presentation
was subliminal.20 Contrary to the experiment by Jensen
et al, the conditioning phase of the present study wasshorter and placebo and nocebo cues were less salient
(stripes vs faces). Further, we did not include so-called
booster trials during the test phase in which placebo
and nocebo cues were paired with the original pain in-
tensity (level of the unconditioned stimulus) from the
conditioning phase to prevent early extinction. Never-
theless, the results of the placebo conditioning phase
and the recalled pain ratings showed that the partici-
pants in the experience group actually learned the con-
tingency of cue and pain stimulation but failed to
generalize during the test phase. One might assume
that in placebo and nocebo conditioning, besides the
length of the conditioning phase13 and the reinforce-
ment pattern,20 the associability of the conditioned reac-
tion to the placebo and nocebo procedure or cue is a
crucial feature that influenced the magnitude of the
resultant placebo response. In favor of this view, in a
recent review3 the necessity to actually attribute a
pain-decreasing effect to a distinct (placebo) treatment
for the successful induction of placebo responses was un-
derscored, as was the case in the combined
expectation 1 experience group of the present study.
Furthermore, Atlas andWager put forward a conceptual
distinction between placebo paradigms that provide a
placebo agent or sham treatment and experimental de-
signs that simply evoke varying outcome expectations,
for instance when cues predict high or low pain stimula-
tion.3 In the present study, the manipulation of expecta-
tion alone resulted only in a small modulation of pain.
However, in previous experiments, placebo effects were
induced only by verbal suggestion,39 and nocebo re-
sponses were elicited even after a single announcement
of the likely occurrence of negative symptoms13 or when
a participant was led to believe that the administration
of an analgesic drug administration had been stopped.7
The method of instruction of a placebo treatment was
shown to affect its final outcome: Uncertain compared
with certain expectations were found to induce smaller
placebo responses.33 It is noteworthy that nearly all of
the studies reviewed so far provided a placebo instruc-
tion that was pharmacologically intuitive. In the present
study, instead, a short and rather abstractwritten instruc-
tion was given, which alone did not suffice to induce a
significant placebo–nocebo response during the test
phase. However, when the predictions about the pain-
modifying properties of the visual black and white stripe
patterns were reassured during placebo–nocebo condi-
tioning (expectation 1 experience), a significant pla-
cebo–nocebo differentiation was elicited on the
behavioral and on the physiological levels. These results
fit very well with previous findings that showed the
strongest placebo effect for the combination of placebo
instruction and conditioning13,25,39 and suggest that
expectation and actual experience interact in an
overadditive manner, mutually reinforcing each other.
In contrast to earlier findings, the placebo–nocebo
agent of the present study consisted of a purely psycho-
logical, nonpharmacologically driven procedure. This
potentially provided lower levels of persuasiveness and
therefore resulted in less pronounced differences as
shown by the results of the expectation group. The
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instructions are provided, it is necessary to confirm their
effectiveness and potency with an actual experience. By
introducing an additional neutral control condition,
experiment 2a and especially 2b showed that a psycho-
logical placebo–nocebo manipulation evoked predomi-
nantly nocebo responses, as shown by the more
pronounced differences between nocebo and control
trials than between placebo and control trials. This sup-
ports earlier findings that showed that nocebo effects
might be achieved more rapidly than placebo effects13
because they rely on shorter learning periods and subse-
quently persist longer in time.29 Interestingly, in experi-
ment 2b, in which the medium temperature of the
control condition during the conditioning phase served
as the test temperature, the ratings for the control con-
dition seemed to decrease during the test compared
with the conditioning phase. Instead, in experiments 1
and 2a, ratings of nocebo trials (which were always at
the same, high-temperature level) seemed to increase
during the test compared with the conditioning phase.
This showed that methodological differences (such as
the temperature level of test stimuli and the condition-
ing procedure) should be carefully taken into account
in comparisons of results of different experiments.
Also, temporal dynamics of placebo and nocebo effects
should be addressed more thoroughly. Regarding the
present design, we assumed that comparisons of
different experimental conditions at similar time points
might be the least biased approach.
In a recent model on the generation of placebo hypo-
algesia it was proposed that the placebo response is the
result of a recurrent integration of bottom-up informa-
tion (ie, sensory, nociceptive input) and top-down pro-
cesses (ie, previous experiences and expectations).8
According to the model, the magnitude of the placebo
response relied on the certainty that a (placebo) treat-
ment would actually be administered and the expecta-
tion regarding the potency of the treatment, which is,
in part, the result of previous experiences. In line with
this view, it was shown that treatment history has an
immense effect on future treatment outcome, such
that a positive placebo experience promoted the placebo
response in a follow-up session and even could be trans-
ferred to a different placebo agent.23 In general, the
treatment history was discussed to shape the individual
attitude toward medical interventions, to moderate the
actual treatment outcome, and to affect placebo and no-
cebo responses.6,16,24 Consequently, placebo paradigms
that are unfamiliar to a participant are necessary and
thus allow circumvention of any confounding factors
that might arise because of the resemblance to earlier
treatments when expectation and experience are
meant to be kept apart. Therefore, the present design
provided an ideal paradigm to further disentangle
mechanisms that constitute placebo and nocebo
effects. Future studies might elaborate methodological
issues of placebo and nocebo effects on the basis of the
considerations that motivated the present study. For
instance, it was shown that an intensive, procedural
therapy resulted in stronger effects than theadministration of a pill alone.21 Similarly, a neuromodu-
lator like oxytocin was found to support the feeling of
trustworthiness and hence placebo analgesia.22 These
findings might be replicated in circumstances in which
the applied agent is not familiar to the participants
and therefore a reference to earlier medical treatments
is less salient. Probably the most ambitious challenge
will represent the surreptitious substitution of ‘‘real’’
agents with psychological placebos, following the logic
of placebo-controlled dose reduction15 when the admin-
istration of a drug is initially combined and later on
completely replaced by a placebo treatment, saving re-
sources and reducing physiological side effects. In addi-
tion, future studies in clinical samples should evaluate
whether pain modulatory placebo and nocebo mecha-
nisms resemble those in healthy control subjects. Some
investigators have shown that in patient samples, the
placebo effect serves to reduce hyperalgesia or patho-
logically altered pain responses.29,30 This might be a
very different process than the typical analgesic or
hypoalgesic response seen in asymptomatic individuals.
Most important, upcoming experiments will need to
sensitively evaluate the individual treatment history
and investigate its effect on treatment outcome and
placebo and nocebo responses.
Several limitations need to be considered in interpre-
tation of the results of the present study. The experi-
mental paradigm of experiment 1 was best suited to
investigate placebo effects because the temperature
during the test phase was identical to the nocebo tem-
perature of the conditioning phase. To maximize con-
trasts between conditions, we chose to instruct
opposing effects (pain augmentation vs pain relief),
whichmight lead to placebo versus nocebo expectations,
respectively. We therefore referred to the resulting pain
modulation as a placebo–nocebo effect. Furthermore, in
experiment 1 the successful induction of expectations
could only be assumed indirectly according to the re-
called pain ratings of the expectation group. This
assumption was also supported by a priori expectancy
ratings of experiment 2 (Fig 5), which comprised a very
similar manipulation. However, explicit expectation rat-
ings would have been informative to more precisely
disentangle the involved processes.
Regarding the results of experiment 1, smaller differ-
ences in sensory compared with affective pain ratings
might have been because of the wording of verbal an-
chors for the sensory and affective pain VAS: The upper
end point of the sensory VAS ‘‘unbearable pain’’ (sensory
pain component) likely did not match the corresponding
end point of the affective VAS ‘‘extremely unpleasant’’
(affective pain component) and therefore might have
lead to a different range within the ratings. However,
the results of all 3 experiments did not show systematic
differences for sensory and affective pain ratings.
The results of experiment 2b suggest increased nocebo
responses, but it cannot be excluded that this effect was
partially driven by an already more pronounced
perceived difference between nocebo and control trials
during conditioning. Such an alternative explanation
could be potentially circumvented by psychophysically
Reicherts et al The Journal of Pain 213calibrated pain stimulation levels, which take into ac-
count the nonlinearity of heat pain perception.28 Differ-
ences in magnitude of (purely psychological) placebo
and nocebo effects demand additional research and
replication; similarly, the successful induction especially
of placebo analgesia by psychological means should be
further addressed in future studies. In experiment 1,
SCR results revealed a significant modulation by placebo
and nocebo conditions only in the beginning of the test
phase. This indicated that physiological effects were
rather short-lasting and restricted to the paradigm in
which only 2 conditions were compared.
In summary, the present study showed that it is
possible to induce alterations of pain perception by a
purely psychological placebo–nocebo manipulation
that does not rely on any earlier associative learning ex-
periences such as past medical treatments. The results
showed an overadditive interaction of a suggestion-
induced expectation and its subsequent affirmationthrough classical conditioning, which were sufficient to
change physiological responses and behavioral measures
of pain. Moreover, our results point to the importance of
a combination of expectation and experience when the
introduced pain modulatory mechanism is psychological
and hence less conventional. Obviously, exploiting pla-
cebo effects is a crucial feature of medical practice; how-
ever, as previous and our current results show, the
efficient prevention of nocebo effects might be at least
equally important. Overall, the presented placebo–no-
cebo paradigm provided a promising avenue for further
research on the psychological foundations of placebo
and nocebo effects.Acknowledgments
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